vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»vsp-1251Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWПРИМЕНЕНИЕ КРЕМА ПИМЕКРОЛИМУСА В ТЕРАПИИ АТОПИЧЕСКОГО ДЕРМАТИТА ПРИ ЛОКАЛИЗАЦИИ ВЫСЫПАНИЙ В ОБЛАСТЯХ С ТОНКОЙ И ЧУВСТВИТЕЛЬНОЙ КОЖЕЙPIMECROLIMUS APPLICATION IN TREATMENT FOR ATOPIC DERMATITIS DURING LOCALIZATION OF THE SKIN RASH IN AREAS WITH THIN AND SENSITIVE SKINТрусоваО.В.TrusovaO.V.КоростовцевД.С.KorostovtsevD.S.Санкт-Петербургская государственная педиатрическая медицинская академияРоссияSaint Petersburg State Pediatric Medical AcademyRussian Federation20072110201564Вопросы современной педиатрии5458Copyright © Трусова О., Коростовцев Д., 20072007Трусова О., Коростовцев Д.Trusova O., Korostovtsev D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/1251ReferencesEllis C., Luger T. II Международная согласительная конференция по атопическому дерматиту (ICCAD II). Аллергология. 2003; 4: 49–59.Ellis C., Luger T. II Международная согласительная конференция по атопическому дерматиту (ICCAD II). Аллергология. 2003; 4: 49–59.Макарова И.В. Диетотерапия и комплексный подход к наружному лечению при атопическом дерматите у детей. СПб.: МедМассМедиа. 2005. 76 с.Макарова И.В. Диетотерапия и комплексный подход к наружному лечению при атопическом дерматите у детей. СПб.: МедМассМедиа. 2005. 76 с.Hoeger P.H., Ott H. Противовоспалительная терапия атопической экземы у детей – традиционные стратегии и новые терапевтические возможности. Аллергология. 2004; 2: 39–47.Hoeger P.H., Ott H. Противовоспалительная терапия атопической экземы у детей – традиционные стратегии и новые терапевтические возможности. Аллергология. 2004; 2: 39–47.Breuer K., Braeutigam M., Kapp A., Werfel T. Influence of pimecrolimus cream 1 % on different morphological signs of eczema in infants with atopic dermatitis. Dermatology. 2004; 209: 314–320.Breuer K., Braeutigam M., Kapp A., Werfel T. Influence of pimecrolimus cream 1 % on different morphological signs of eczema in infants with atopic dermatitis. Dermatology. 2004; 209: 314–320.Zuberbier T., Orlow S.J., Paller A.S. et al. Patient perspectives on the management of atopic dermatitis. J. Allergy Clin. Immunol. 2006; 118: 226–232.Zuberbier T., Orlow S.J., Paller A.S. et al. Patient perspectives on the management of atopic dermatitis. J. Allergy Clin. Immunol. 2006; 118: 226–232.Pariser D., Paller A., Langley R., Paul C. Efficacy and local tolerability of pimecrolimus cream 1 % in the treatment of atopic dermatitis in the face/neck region of pediatric subjects. J. Invest. Dermatol. 2002; 119: 348 (Abstr. 845).Pariser D., Paller A., Langley R., Paul C. Efficacy and local tolerability of pimecrolimus cream 1 % in the treatment of atopic dermatitis in the face/neck region of pediatric subjects. J. Invest. Dermatol. 2002; 119: 348 (Abstr. 845).Eichenfield L.F., Lucky A.W., Boguniewicz M. et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1 % in the treatment of mild and moderate atopic dermatitis in children and adolescents. J. Am. Acad. Dermatol. 2002; 46: 495–504.Eichenfield L.F., Lucky A.W., Boguniewicz M. et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1 % in the treatment of mild and moderate atopic dermatitis in children and adolescents. J. Am. Acad. Dermatol. 2002; 46: 495–504.Ho V.C., Gupta A., Kaufman R. et al. Safety and efficacy of nonsteroid pimecrolimus cream 1 % in the treatment of atopic dermatitis in infants. J. Pediatrics. 2003; 142: 155–162.Ho V.C., Gupta A., Kaufman R. et al. Safety and efficacy of nonsteroid pimecrolimus cream 1 % in the treatment of atopic dermatitis in infants. J. Pediatrics. 2003; 142: 155–162.Simon D., Lubbe J., Wuthrich B. et al. Benefits from the use of a pimecrolimus-based treatment in the management of atopic dermatitis in clinical practice. Dermatology. 2006; 213: 313–318.Simon D., Lubbe J., Wuthrich B. et al. Benefits from the use of a pimecrolimus-based treatment in the management of atopic dermatitis in clinical practice. Dermatology. 2006; 213: 313–318.Трусова О.В., Бальцерович Н.Б., Жиглинская О.В. и др. Применение крема Элидел в качестве основного противовоспалительного топического препарата у детей первого года жизни с персистирующим течением атопического дерматита легкой и средней степени тяжести. Аллергология. 2006; 1: 15–20.Трусова О.В., Бальцерович Н.Б., Жиглинская О.В. и др. Применение крема Элидел в качестве основного противовоспалительного топического препарата у детей первого года жизни с персистирующим течением атопического дерматита легкой и средней степени тяжести. Аллергология. 2006; 1: 15–20.Weise-Riccardi S., Ortonne J.-P., Calvieri S., et al. Randomized vehicle-controlled trial of pimecrolimus 1 % cream in adults with head and neck atopic dermatitis intolerant of, or dependent on, topical corticosteroid. J. Invest. Dermatol. 2006; 126: 46.Weise-Riccardi S., Ortonne J.-P., Calvieri S., et al. Randomized vehicle-controlled trial of pimecrolimus 1 % cream in adults with head and neck atopic dermatitis intolerant of, or dependent on, topical corticosteroid. J. Invest. Dermatol. 2006; 126: 46.Hultsch T., Kapp A., Spergel J. Immunomodulation and safety of topical calcineurin inhibitors. Dermatology. 2005; 211: 174–187.Hultsch T., Kapp A., Spergel J. Immunomodulation and safety of topical calcineurin inhibitors. Dermatology. 2005; 211: 174–187.Paul C., Cork M., Rossi A.B. et al. Safety and tolerability of 1 % pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years. Pediatrics. 2006; 117: 118.Paul C., Cork M., Rossi A.B. et al. Safety and tolerability of 1 % pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years. Pediatrics. 2006; 117: 118.Gottlieb A.B., Griffiths C.E.M., Ho V.C. et al. Efficacy and tolerability of oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial. Br. J. Dermatol. 2005; 152: 1219–1227.Gottlieb A.B., Griffiths C.E.M., Ho V.C. et al. Efficacy and tolerability of oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial. Br. J. Dermatol. 2005; 152: 1219–1227.Van Leent E.J.M., Ebelin M.-E., Burtin P. et al. Low systemic exposure after repeated topical application of pimecrolimus (Elidel®, SDZ ASM 981) in patients with atopic dermatitis. Dermatology. 2002; 204: 63–68.Van Leent E.J.M., Ebelin M.-E., Burtin P. et al. Low systemic exposure after repeated topical application of pimecrolimus (Elidel®, SDZ ASM 981) in patients with atopic dermatitis. Dermatology. 2002; 204: 63–68.Thaçi D., Steinmeyer K., Ebelin M.-E. et al. Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1 % results in low systemic exposure, is well tolerated, safe, and effective. An open study. Dermatology. 2003; 207: 37–42.Thaçi D., Steinmeyer K., Ebelin M.-E. et al. Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1 % results in low systemic exposure, is well tolerated, safe, and effective. An open study. Dermatology. 2003; 207: 37–42.Graham-Brown R.A.C., Grassberger M. Pimecrolimus: a review of pre-clinical and clinical data. Int. J. Clin. Pract. 2003; 57: 319–327.Graham-Brown R.A.C., Grassberger M. Pimecrolimus: a review of pre-clinical and clinical data. Int. J. Clin. Pract. 2003; 57: 319–327.Harper J., Green A., Scott G. et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br. J. Dermatol. 2004; 144: 781–787.Harper J., Green A., Scott G. et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br. J. Dermatol. 2004; 144: 781–787.Allen B.R., Lakhanpaul M., Morris A. et al. Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1 % in atopic dermatitis patients. Arch. Dis. Child. 2003; 88: 969–973.Allen B.R., Lakhanpaul M., Morris A. et al. Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1 % in atopic dermatitis patients. Arch. Dis. Child. 2003; 88: 969–973.Lakhanpaul M., Davies T., Allen B. et al. Pimecrolimus (SDZ ASM 981) cream 1 %: minimal systemic absorption in infants with atopic dermatitis during long term treatment (abstract). Ann. Dermatol. Venereol. 2002; 129 (Suppl.1):415.Lakhanpaul M., Davies T., Allen B. et al. Pimecrolimus (SDZ ASM 981) cream 1 %: minimal systemic absorption in infants with atopic dermatitis during long term treatment (abstract). Ann. Dermatol. Venereol. 2002; 129 (Suppl.1):415.Meurer M., Fölster-Holst R., Wozel G. et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six month study. Dermatology. 2002; 205: 271–277.Meurer M., Fölster-Holst R., Wozel G. et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six month study. Dermatology. 2002; 205: 271–277.Meurer M., Fartasch M., Albrecht G. et al. Long term efficacy and safety of pimecrolimus cream 1 % in adults with moderate atopic dermatitis. Dermatology. 2004; 208: 365–372.Meurer M., Fartasch M., Albrecht G. et al. Long term efficacy and safety of pimecrolimus cream 1 % in adults with moderate atopic dermatitis. Dermatology. 2004; 208: 365–372.Kapp A., Papp K., Bingham A. et al. Flare reduction in eczema with Elidel (infants) multicentre investigator study group: long-term management of atopic dermatitis in infants with pimecrolimus, a nonsteroid anti-inflammatory drug. J. Allergy Clin. Immunol. 2002; 110: 277–284.Kapp A., Papp K., Bingham A. et al. Flare reduction in eczema with Elidel (infants) multicentre investigator study group: long-term management of atopic dermatitis in infants with pimecrolimus, a nonsteroid anti-inflammatory drug. J. Allergy Clin. Immunol. 2002; 110: 277–284.Papp K., Werfel T., Fölster–Holst R. et al. Long-term control of atopic dermatitis with pimecrolimus cream 1 % in infants and young children: a two-year study. J. Am. Acad. Dermatol. 2005; 52: 240–246.Papp K., Werfel T., Fölster–Holst R. et al. Long-term control of atopic dermatitis with pimecrolimus cream 1 % in infants and young children: a two-year study. J. Am. Acad. Dermatol. 2005; 52: 240–246.
The authors declare that there are no conflicts of interest present.